Adicet Bio

ADICET BIO INC

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

analyst ratings image

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

ACET

ANIP

RLAY

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

IN8bio’s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data 

Biotech

Penny Stocks

General

INAB

IPSC

IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.

IN8bio&#39;s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data

Small Cap

Intraday Update

Movers

ACCD

ACMR

AIMD

BETS

BOWL

CENX

CUTR

DECA

GOEV

GRFS

GRTX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

ILMN

JBLU

JNPR

JWEL

KITT

KORE

LDTC

Morgan Stanley Capital Protected Notes for S&P 500 Index

NEOG

NEXI

SNTG

TCJH

TLRY

URBN

VIRI

YCBD

ZCAR

PTHR

Shares of JetBlue Airways Corporation (NASDAQ: JBLU) fell sharply during Tuesday’s session.

Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Adicet Bio Inc

Press Releases

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

BeyondSpring

Cabaletta Bio

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Citius Oncology

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

ImmuCell

I-MAB

Immuneering Corporation - Class A Common Stock

Immuneering

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Inozyme Pharma

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kronos Bio

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PMV Pharma

Pyxis Oncology

Quince Therapeutics

Serina Therapeutics

Sutro Biopharma

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Guggenheim

Wedbush

Jones Trading

Canaccord Genuity

Truist Securities

Aceto Corporation

Comments

Adicet Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga